Clinical Trial Update: A Study of E6201 for the Treatment of Advanced Hematologic Malignancies With FLT3 and/or Ras Mutations [Phase 1, Phase 2]

View source ↗

Summary

Clinical trial update for E6201 in advanced hematologic malignancies with FLT3 and/or Ras mutations (Phase 1/2) shows terminated status; results posted in 2019.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia
• Myelodysplastic Syndrome
• Myelomonocytic Leukemia

Drugs mentioned

• E6201

Snippet

Sponsor: Spirita Oncology, LLC | Conditions: AML, MDS | Phase 1, Phase 2 | Status: TERMINATED | Results posted: 2019-03-05